Cornerstone Advisory LLC Reduces Holdings in UnitedHealth Group Incorporated $UNH

Key Points

• Cornerstone Advisory LLC reduced its stake in UnitedHealth Group by 21.1%, holding 2,600 shares, valued at approximately $811,000.
• UnitedHealth Group reported a missed earnings estimate of $4.08 EPS, falling short of the consensus of $4.45, despite a year-over-year revenue increase of 12.9%.
• The company recently declared a quarterly dividend of $2.21 per share, resulting in an annualized dividend yield of 2.4%.

Cornerstone Advisory LLC trimmed its position in shares of UnitedHealth Group Incorporated (NYSE:UNH - Free Report) by 21.1% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,600 shares of the healthcare conglomerate's stock after selling 696 shares during the quarter. Cornerstone Advisory LLC's holdings in UnitedHealth Group were worth $811,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. Citizens National Bank Trust Department grew its holdings in UnitedHealth Group by 1.0% in the 1st quarter. Citizens National Bank Trust Department now owns 17,886 shares of the healthcare conglomerate's stock valued at $9,368,000 after buying an additional 170 shares in the last quarter. Caitlin John LLC grew its holdings in UnitedHealth Group by 14.8% in the 1st quarter. Caitlin John LLC now owns 862 shares of the healthcare conglomerate's stock valued at $451,000 after buying an additional 111 shares in the last quarter. Triumph Capital Management purchased a new stake in UnitedHealth Group in the 2nd quarter valued at $1,324,000. Wealth Effects LLC grew its holdings in UnitedHealth Group by 14.4% in the 2nd quarter. Wealth Effects LLC now owns 4,688 shares of the healthcare conglomerate's stock valued at $1,463,000 after buying an additional 591 shares in the last quarter. Finally, Arlington Partners LLC purchased a new stake in UnitedHealth Group in the 2nd quarter valued at $2,229,000. 87.86% of the stock is currently owned by hedge funds and other institutional investors.

UnitedHealth Group Price Performance

UNH opened at $361.29 on Thursday. The stock's 50-day moving average price is $335.48 and its 200 day moving average price is $341.42. UnitedHealth Group Incorporated has a 12-month low of $234.60 and a 12-month high of $630.73. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 0.73. The firm has a market cap of $327.21 billion, a price-to-earnings ratio of 15.65, a PEG ratio of 2.36 and a beta of 0.47.

UnitedHealth Group (NYSE:UNH - Get Free Report) last posted its earnings results on Tuesday, July 29th. The healthcare conglomerate reported $4.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.45 by ($0.37). The firm had revenue of $111.62 billion for the quarter, compared to analyst estimates of $111.75 billion. UnitedHealth Group had a return on equity of 23.32% and a net margin of 5.04%.UnitedHealth Group's revenue was up 12.9% on a year-over-year basis. During the same period in the previous year, the company posted $6.80 EPS. UnitedHealth Group has set its FY 2025 guidance at 16.000- EPS. As a group, sell-side analysts expect that UnitedHealth Group Incorporated will post 29.54 earnings per share for the current year.

UnitedHealth Group Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 23rd. Shareholders of record on Monday, September 15th were given a $2.21 dividend. The ex-dividend date of this dividend was Monday, September 15th. This represents a $8.84 dividend on an annualized basis and a yield of 2.4%. UnitedHealth Group's dividend payout ratio (DPR) is currently 38.30%.

Analysts Set New Price Targets

UNH has been the topic of several recent analyst reports. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $440.00 price target on shares of UnitedHealth Group in a research note on Tuesday, August 26th. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of UnitedHealth Group in a research note on Wednesday, October 8th. KeyCorp upped their price target on UnitedHealth Group from $350.00 to $400.00 and gave the company an "overweight" rating in a research note on Wednesday, October 8th. JPMorgan Chase & Co. upped their price target on UnitedHealth Group from $310.00 to $425.00 and gave the company an "overweight" rating in a research note on Thursday, October 9th. Finally, Truist Financial upped their price target on UnitedHealth Group from $310.00 to $365.00 and gave the company a "buy" rating in a research note on Tuesday, September 9th. Eighteen investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $385.13.

UnitedHealth Group Company Profile

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.